Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014

Findings from a recent cohort study published in Diabetes Care (1), which included >740,000 individuals with type 2 diabetes (T2D) aged ≥65 years, demonstrated that both sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) were associated with smaller numbers of cardiovascular events and death than dipeptidyl peptidase 4 inhibitors (DPP-4i), with the largest benefits being seen among frail people. Adverse events that affected frailer individuals were not more common with SGLT2i or GLP-1RAs than with DPP-4i (1).


http://dlvr.it/T4cnLx